J&J Talc Settlement Status 2026: The $5.5 Billion Ovarian Cancer Deal and What Happens Next

For more than a decade, women and their families have sued Johnson & Johnson, alleging that talc-based products such as Johnson's Baby Powder caused ovarian cancer, and in other cases mesothelioma from asbestos-contaminated talc. Federal ovarian cancer cases are consolidated in In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation, MDL No. 2738, in the District of New Jersey, before Judge Michael A. Shipp and Magistrate Judge Rukhsanah L. Singh.

J&J's July 27, 2026 announcement describes a comprehensive resolution of the remaining ovarian talc litigation, reached with the plaintiff firms leading the MDL and related state court cases. Reuters reported the deal covers about 76,000 claims, nearly all of the remaining talc claims against the company. J&J says it previously settled about 95% of filed mesothelioma lawsuits, all state consumer protection claims, and its disputes with talc suppliers.

J&J denies its talc products cause cancer and calls the claims meritless. The company stopped selling talc-based baby powder in the U.S. in 2020 and switched to cornstarch, according to Reuters. For the full background, see our talc ovarian cancer lawsuit page.

The proposal came days after a major ruling in the MDL. On July 22, 2026, the MDL court ordered plaintiffs to show why their remaining talc claims should not be dismissed for inability to prove specific causation, meaning proof that talc caused a particular person's cancer. J&J says the order followed plaintiffs' withdrawal of their specific causation experts in two bellwether cases.

Date	Event
2020	J&J stops selling talc baby powder in the U.S.
2021 to 2025	Three subsidiary bankruptcy attempts, each dismissed
March 2025	Litigation resumes after the last bankruptcy is dismissed
July 22, 2026	MDL order to show cause on specific causation
July 27, 2026	J&J announces $5.5 billion proposed resolution

Reuters reported that litigation had been paused for more than three years while J&J pursued the so-called "Texas two-step," filing three bankruptcies through a subsidiary to settle the cases. Each ended in dismissal. Unlike those plans, this deal pays only existing claims.

J&J describes the deal as calling for per-claim payments backed by a $5.5 billion commitment, with the first payment of no more than $3 billion in 2027 and no additional payments due before 2028. Chris Seeger, a plaintiffs' lawyer who helped negotiate it, told Reuters that the settlement assigns specific values to qualifying ovarian cancer claims, does not cap J&J's total payout, and could ultimately cost J&J $7 billion or more. He also said all claims would be paid within 18 months.

No official per-person figure has been published. Simple division of $5.5 billion by about 76,000 claims gives roughly $72,000 per claim, but that is only an average. Actual amounts will depend on the grid, each person's diagnosis and records, and legal fees, which in mass torts come out of each client's recovery under their own fee agreement. See who pays the lawyers and whether settlement money is taxed.

This is not a class action with a settlement website. Participation happens through each claimant's attorney:

1. Your lawyer reviews the terms and the value your claim would receive under the grid.
2. You decide whether to opt in. The deal needs express participation covering at least 95% of remaining claims to take effect.
3. Documentation is reviewed. Expect to need medical records confirming the diagnosis and evidence of talc product use; your lawyer handles submission.
4. Payments follow if the participation threshold and other conditions are met, beginning in 2027 per J&J.

If you have a filed talc case, only your own attorney can tell you what your claim is worth under the grid. Be wary of anyone else offering to "enroll" you. See our guide to the difference between class actions and mass torts.

Item	Status
Deal announced	July 27, 2026
Participation threshold	At least 95% of remaining claims
First payment	2027, up to $3 billion
Later payments	Not before 2028
Public claim deadline	None (not a class action)

As of September 2026, J&J had not announced that the 95% participation threshold was met, and the MDL court's order requiring plaintiffs to justify their claims remained a pressure point. If the deal fails, cases return to the MDL and state courts, where claimants would need expert proof of specific causation.

The proposed settlement applies only to existing claims and does not address future lawsuits, according to Reuters. Someone diagnosed with ovarian cancer who never filed is not part of it. Whether a new claim is still possible depends on your state's statute of limitations, often measured from diagnosis or from when you learned of a possible link, and on the MDL's specific causation rulings, which make new ovarian cancer claims harder.

Mesothelioma claims tied to asbestos in talc are a separate track that J&J has largely settled case by case; see our mesothelioma and asbestos lawsuit page. These remain allegations unless a court or jury rules. If you or a family member has a diagnosis and used talc products for years, a free case review can connect you with independent attorneys who handle talc cases, and you can see other active claims on our lawsuits to join page.